Forgot Password?
Return to Course Listing

CME: Updates in the pharmacotherapeutic management of familial hypercholesterolemia (FH): present and emerging treatment options

ACCREDITATION EXPIRED: October 22, 2020

Activity Description / Statement of Need:

In this online, self-learning activity:

Familial hypercholesterolemia (FH), also known as type II hyperlipoproteinemia, is an autosomal dominant disorder characterized by elevated plasma LDL-C levels in the absence of hypertriglyceridemia (or if triglycerides are elevated, they are so independently of FH). There are over 1,600 different mutations associated with FH, and the condition arises from a significant reduction in functional LDL-C receptors (LDL-Rs) – half in the case of heterozygous patients and practically none in the case of homozygous patients – and an attendant reduced rate of LDL-C clearance that predisposes an individual to premature atherosclerotic cardiovascular disease. If the LDL-C levels in a patient are greater than the 95th percentile for age and sex, it is likely that the person has a genetic cause for their hypercholesterolemia and the treatment goal is to prevent cardiovascular disease and cardiovascular related events. Analyses of data from the National Health and Nutrition Examination Survey (NHANES) suggest that the prevalence of FH in the U.S. is about 1 in every 299 persons.

Target Audience:

The following healthcare professionals: cardiology and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in cardiology; and any other clinicians with an interest in FH.

Commercial Support Disclosure: This program is supported by an educational grant from Amgen.

Release Date: October 22, 2018 -- Expiration Date: October 22, 2020

Faculty: John A. Tayek, MD

Agenda

Faculty introduction, disclosures

Introduction content: cursory refresher and review of FH

  • Updates in statistics
  • Homozygous and heterozygous FH
  • Xanthoma development, vascular disease occurrence

Treatment and management of FH

  • Clinical trial findings and guideline remarks
  • Pharmacotherapy
  • Conventional therapy
  • PCSK-9 inhibitors
  • Lomitapide
  • Mipomersen
  • Other clinical pearls
  • Emerging and future therapies
  • Barriers to optimal care in patients with FH
  • Best practice: putting it all together
  • Patient case(s)

Summary, conclusions, and best practice recap

Learning Objectives

By the end of the session the participant will be able to:

  • Describe the pathophysiology and genetics of FH such that they might inform treatment mechanisms
  • Describe presently available and emerging treatment options for FH and apply them to patient cases
  • Evaluate a FH treatment plan and suggest modifications for improvement
  • Describe clinical and logistical challenges associated with treating and educating patients with FH

Accreditation

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.


Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

 

Faculty Disclosure: John A. Tayek, M.D., Professor of Medicine-In Residence David Geffen School of Medicine at UCLA Harbor-UCLA Medical Center, has received research support from Ajinomoto and Amarin Pharma.

 

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP has no relevent financial disclosures.

 

Commercial Support Disclosure: This program is supported by an educational grant from Amgen.

Instructions

  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

PC
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
MAC
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.